Memorial Sloan Kettering Cancer Center 10th Annual MSK Symposium on Lymphoma 2026
Advanced Updates in Lymphoma Diagnosis, Classification & Precision Oncology
The 10th Annual MSK Symposium on Lymphoma 2026 marks a decade of excellence in lymphoma education, bringing together internationally recognized experts in hematology, oncology, pathology, and translational research. Hosted by Memorial Sloan Kettering Cancer Center (MSKCC), this one-and-a-half-day symposium provides a comprehensive review of the rapidly evolving landscape of lymphoma diagnosis, classification, disease biology, and therapeutic innovation.
Designed for clinicians involved in the care of patients with lymphoma, the program explores recent advances in the WHO and International Consensus Classification (ICC) systems, emerging biomarkers, novel targeted therapies, cellular immunotherapies, and management strategies for both newly diagnosed and relapsed/refractory lymphoma.
Through keynote presentations, case-based panel discussions, and expert clinical guidance, participants gain practical insights into applying the latest scientific discoveries to individualized patient care.
Product Details
- Course: 10th Annual MSK Symposium on Lymphoma
- Provider: Memorial Sloan Kettering Cancer Center (MSKCC)
- Course Dates: April 10–11, 2026
- Location: Zuckerman Research Center, New York, NY
- Format: In-Person & Virtual
- Course Year: 2026
Program Overview
This advanced lymphoma symposium provides state-of-the-art updates across the spectrum of lymphoma care.
Key areas of focus include:
- Lymphoma Biology
- WHO & ICC Lymphoma Classification Updates
- Diagnostic Hematopathology
- B-Cell Lymphomas
- T-Cell Lymphomas
- Hodgkin Lymphoma
- Relapsed/Refractory Disease
- Targeted Therapies
- Immunotherapy
- Bispecific Antibodies
- CAR T-Cell Therapy
- Precision Medicine
- Shared Decision-Making
- Translational Research
The curriculum bridges emerging scientific discoveries with real-world clinical application.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Apply updated WHO and ICC lymphoma classification systems in clinical practice.
- Evaluate current first-line treatment strategies for common lymphoma subtypes.
- Discuss the mechanisms of action, efficacy, and toxicity profiles of novel lymphoma therapies.
- Implement evidence-based approaches for relapsed and refractory lymphoma.
- Incorporate precision medicine strategies into lymphoma management.
- Utilize shared decision-making principles to optimize treatment planning.
- Recognize emerging developments in lymphoma biology and translational research.
- Improve multidisciplinary collaboration in lymphoma care.
Core Topics Covered
Lymphoma Classification Updates
The course reviews major developments in:
- WHO Classification Updates
- International Consensus Classification (ICC)
- Molecular Diagnostics
- Biomarker Integration
- Disease Subtyping
Participants learn how modern classification systems influence diagnosis and treatment selection.
B-Cell Lymphomas
Comprehensive sessions explore:
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Aggressive B-cell Neoplasms
Experts discuss evolving treatment paradigms and risk-adapted strategies.
Hodgkin Lymphoma
Topics include:
- Frontline therapy
- Risk stratification
- PET-guided management
- Novel immunotherapies
- Relapsed disease management
Faculty review current standards and future directions in care.
T-Cell & Rare Lymphomas
Specialized discussions address:
- Peripheral T-cell lymphomas
- Cutaneous lymphomas
- Rare lymphoma subtypes
- Diagnostic challenges
- Emerging treatment options
Participants gain practical insights into managing uncommon and complex cases.
Novel Therapeutics
The symposium highlights:
- Bispecific antibodies
- Antibody-drug conjugates
- Small molecule inhibitors
- Targeted therapies
- Immunotherapy combinations
Experts review efficacy data and toxicity management strategies.
CAR T-Cell Therapy
Sessions focus on:
- Patient selection
- Cellular therapy logistics
- Response assessment
- Cytokine release syndrome (CRS)
- Neurotoxicity management
- Long-term outcomes
Participants gain updates on one of the most rapidly evolving areas in lymphoma care.
Relapsed & Refractory Lymphoma
Key discussions include:
- Treatment sequencing
- Salvage therapy
- Cellular therapy integration
- Clinical trial opportunities
- Personalized treatment strategies
Faculty review approaches for difficult-to-treat lymphoma cases.
Precision Medicine & Translational Research
Topics include:
- Genomic profiling
- Molecular biomarkers
- Predictive testing
- Target discovery
- Future therapeutic directions
The program highlights how advances in biology are transforming patient care.
Shared Decision-Making
Participants learn strategies for:
- Patient-centered communication
- Treatment goal discussions
- Risk-benefit assessment
- Survivorship planning
- Long-term care coordination
Practical guidance is provided for individualized treatment planning.
Educational Features
✔ International Lymphoma Experts
✔ WHO & ICC Classification Updates
✔ Precision Oncology Applications
✔ CAR T-Cell Therapy Advances
✔ Bispecific Antibody Updates
✔ Case-Based Panel Discussions
✔ Translational Research Highlights
✔ Multidisciplinary Clinical Perspectives
Target Audience
This course is ideal for:
- Hematologists
- Medical Oncologists
- Radiation Oncologists
- Hematopathologists
- Internal Medicine Physicians
- Oncology Fellows
- Hematology Fellows
- Pathologists
- Advanced Practice Providers
- Oncology Pharmacists
- Researchers & Scientists
- Medical Trainees
Why This Course Stands Out
✔ Celebrates the 10th anniversary of MSK’s premier lymphoma symposium
✔ Features internationally recognized lymphoma experts
✔ Comprehensive review of modern lymphoma classification systems
✔ Strong focus on emerging therapies and precision medicine
✔ Covers both common and rare lymphoma subtypes
✔ Includes practical guidance for relapsed and refractory disease
✔ Integrates pathology, translational science, and clinical oncology
✔ Provides immediately applicable clinical insights
Clinical & Educational Value
The Memorial Sloan Kettering Cancer Center 10th Annual MSK Symposium on Lymphoma 2026 provides an in-depth review of the latest advances in lymphoma diagnosis, classification, and treatment. Through expert-led lectures, multidisciplinary discussions, and cutting-edge research updates, participants gain valuable knowledge on modern lymphoma management, novel therapeutics, cellular immunotherapy, and precision oncology. The course equips clinicians with the tools needed to deliver personalized, evidence-based care for patients with lymphoma.
Topics
-
A “Path” Toward Diagnosis- An Overview of Pathology in Lymphoma
-
Advances in Therapeutic Strategies for Mantle Cell Lymphoma
-
Bridging, Debulking, and Beyond- The Multifaceted Role of Radiotherapy with CAR T Cells and Bispecifics
-
CAR T-Cell Therapy- Lessons Learned from the DESCAR-T Registry
-
Concepts and Controversies in Aggressive B-Cell Lymphoma Classification
-
Current Challenges in the Management of Patients with Follicular Lymphoma
-
Debate- Is a Follicular Lymphoma Cure in Reach- T-Cell Engagers versus CAR T-Cell Therapy
-
Diffuse Large B-Cell Lymphoma- Diagnosis and Updates on Management
-
Diffuse Large B-Cell Lymphoma Panel Discussion and Q&A
-
Follicular Lymphoma Panel Discussion and Q&A
-
Hodgkin Lymphoma Panel Discussion and Q&A
-
HTLV-1 Clinic Overview
-
HTLV-1-Associated Lymphoma-Leukemia- Biology
-
HTLV-1-Associated Lymphoma-Leukemia- Epidemiology and Natural History
-
HTLV-1-Associated Lymphoma-Leukemia- Therapies
-
Innovations in T-Cell Lymphoma- A Winding Road
-
Insights into the Molecular Classification of Diffuse Large B-Cell Lymphoma
-
Integrative Medicine- Management of Treatment Related Side Effects
-
Introduction to Cutaneous T-Cell Lymphoma
-
Lessons Learned from the Development of T-Cell-Engaging Antibodies in B-Cell Lymphoma
-
Mantle Cell Lymphoma Panel Discussion and Q&A
-
Mechanisms of Resistance to BTK Degraders
-
Optimizing First-Line Therapy- Balancing Efficacy versus Toxicity
-
Optimizing First-Line Therapy in Diffuse Large B-Cell Lymphoma
-
Panel Discussion and Q&A
-
Plenary Lecture- Designing the Next Generation of CAR T-Cell Therapies for Lymphoma
-
Plenary Lecture Panel Discussion and Q&A
-
Recent Advances in the Management of Chronic Lymphocytic Leukemia
-
Research Spotlight- Bispecific B Cell Protocols at MSK and CRS management
-
Skin Considerations for Cutaneous T-Cell Lymphoma
-
Small Doses, Big Impact- The Role of Very Low-Dose Radiotherapy in Potentially Curable Indolent Lymphomas
-
Special Lecture- B-Cell Development and Lineage Stability
-
Special Lecture- How to Interpret “Real-World” Data
-
Spotlight on New Agents and MSK Clinical Trials
-
Spotlight on Nodular Lymphocyte Predominant B-Cell- Hodgkin Lymphoma
-
Spotlight on Recent Drugs and MSK Clinical Trials – 01
-
Spotlight on Recent Drugs and MSK Clinical Trials
-
T-Cell Lymphoma Panel Discussion and Q&A
